Hepatitis B Reactivation
8
0
2
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
38%
3 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue
Prophylactic Entecavir for HBV Reactivation in Past HBV Infected Patients With Hematopoietic Stem Cell Transplantation
TAF to Prevent HBV Reactivation in Cancer Patients
TDF and Entekavir - Hepatitis B Reactivation
DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)
HBV Vaccine in Anti-core Positive Donors After LT
Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL